PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial) Investigators Selected Research

Hemorrhage

1/2018

Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial) Investigators Research Topics

Disease

1	Hemorrhage 01/2018
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2018
1	Pulmonary Embolism 01/2018
1	Critical Illness (Critically Ill) 01/2018
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2018

Drug/Important Bio-Agent (IBA)

1	CreatinineIBA 01/2018
1	Heparin (Liquaemin)FDA LinkGeneric 01/2018
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2018
1	Dalteparin (Dalteparin Sodium)FDA Link 01/2018